New pill targets rosacea inflammation at its source
NCT ID NCT07681271
First seen Jul 02, 2026 · Last updated Aug 13, 2026 · Updated 6 times
Summary
This study tests an oral medication called remibrutinib for adults with moderate-to-severe papulopustular rosacea, a skin condition causing red bumps and pustules on the face. The drug works by blocking a protein involved in inflammation. Researchers will measure whether it reduces the number of facial lesions compared to a placebo, and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remibrutinib (LOU064)
- What this could lead to
- If successful, this could offer a new oral treatment option for people with moderate-to-severe papulopustular rosacea, reducing facial bumps and pustules.
- What could go wrong
- This is an early Phase 2 study with only 80 participants, so results may not confirm effectiveness or safety. The drug may cause side effects or fail to outperform placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPULOPUSTULAR ROSACEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGLondon, Ontario, N6H 5L5, Canada
-
Novartis Investigative Site
RECRUITINGMarkham, Ontario, L3P 1X3, Canada
-
Novartis Investigative Site
RECRUITINGDongjak Gu, Seoul, 07061, South Korea
-
Three A Research
RECRUITINGEl Paso, Texas, 79902, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.